IBD & Crohn's Support

BPC-157 was originally isolated from gastric juice, and research suggests it has cytoprotective activity throughout the GI tract when taken orally. While injectable BPC-157 circulates systemically, oral administration concentrates the peptide along the entire gut epithelium — the precise site of pathology in IBD and Crohn's. Multiple rat models of colitis, intestinal anastomosis, and fistula healing show strong protective effects with oral dosing.

Animal models of acute colitis show BPC-157 significantly reduces inflammatory markers and mucosal damage even when administered after disease induction — suggesting potential benefit during active flares. It has not been studied in human RCTs for this indication. Given its safety profile and lack of known contraindications with standard IBD medications, some researchers use it as an adjunct during flares while maintaining their prescribed treatment.

Research protocols for oral BPC-157 in gut conditions typically use 250–500mcg twice daily, dissolved in water on an empty stomach. Some researchers prefer to open capsules (if using capsulated form) directly into water for better distribution. Cycles of 4–8 weeks are common. Unlike subcutaneous BPC-157, oral administration appears to act locally in the gut with minimal systemic absorption.